40 results on '"Hassel, Jessica C"'
Search Results
2. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
3. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade
4. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
5. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis
6. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
7. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
8. Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
9. MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study
10. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis
11. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
12. Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study
13. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
14. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
15. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
16. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
17. Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group
18. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study
19. Melanoma brain metastases – Interdisciplinary management recommendations 2020
20. IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression
21. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
22. 5-year results for pembrolizumab treatment of advanced melanoma
23. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases
24. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma
25. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
26. Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy
27. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
28. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
29. The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice
30. Ipilimumab plus nivolumab for advanced melanoma
31. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
32. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
33. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
34. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
35. RAS Mutations in Benign Epithelial Tumors Associated with BRAF Inhibitor Treatment of Melanoma
36. Comparison of molecular abnormalities in vulvar and vaginal melanomas
37. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients
38. Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor
39. Predicting tooth color from facial features and gender: Results from a white elderly cohort
40. STAT5 Contributes to Interferon Resistance of Melanoma Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.